The Board of Hepatitis Australia, the peak body leading the national community response to viral hepatitis, is delighted to announce the appointment of Lucy Clynes as CEO commencing 5 August 2024.

Professor Joe Doyle, President of Hepatitis Australia said:

“Hepatitis Australia is delighted to announce Lucy’s appointment as CEO. Lucy brings a breadth of experience and expertise in government decision-making and policy development, including ensuring the voice of community is embedded in national policy.

“Lucy is an advocacy specialist with a track record building strategic partnerships to achieve policy and funding outcomes.

“We are excited to have Lucy joining our team to build on our progress and lead Australia’s efforts to eliminate hepatitis B and hepatitis C.”

Lucy is currently General Manager of Research Australia, the national peak body for Australian health and medical research. She has led the development of medical research strategy for governments, health care providers and health charities. Lucy has supported the voice of health and medical research participants to be embedded across the research pipeline.  

Prior to joining Research Australia in 2016, Lucy was a practising lawyer and held policy roles across both state and federal government, including working as Deputy Chief of Staff for a government minister.  

On her appointment, Lucy said:

“Hepatitis Australia is a highly respected peak organisation and its role in representing the communities affected by viral hepatitis is critical to progressing Australia’s 2030 elimination agenda. I’m delighted to be joining the team and I look forward to building on the incredible work so far.”

Australia is moving into the next critical phase of its elimination journey, with substantial new investments announced in the 2024/25 federal budget and national strategies set to be released.